Quick Facts: Mercilon 28 Main Uses

• Primary Indication: Supports the prevention of pregnancy (contraception).
• Associated Benefits: May contribute to more regular and generally lighter menstrual bleeding.
• Menstrual Support: Can assist in mitigating symptoms often associated with menstruation, such as menstrual cramps.

---

Mercilon 28 is a combined hormonal medication indicated for contraception, working to support the management of pregnancy risk. It is a recognized and established form of reversible birth control when taken as directed.

This medication provides support against unintended pregnancy through hormonal action, which typically involves inhibiting the monthly release of an egg (ovulation). Additionally, it may work by thickening cervical fluid, which can make it more difficult for sperm to reach an egg.

Beyond its primary use, Mercilon 28 is associated with non-contraceptive benefits. Users commonly report that the regimen may lead to more predictable, shorter, and generally lighter menstrual periods. This change in bleeding pattern may potentially assist in reducing discomfort associated with menstruation, such as cramps. Patients should note that, as with any medication, individual responses can vary.

Eligibility: Who Can and Cannot Use Mercilon 28

Official regulatory documentation establishes strict population rules for using Mercilon 28, a combined oral contraceptive (COC), limiting use to females of reproductive potential. Eligibility is defined primarily by the exclusion of groups with specific health risks or physiological states.

Contraindicated Populations (Must Not Use)

Primary Exclusion	Examples of Condition
Thromboembolic Risk	Current/history of VTE, ATE, or known thrombophilia (e.g., Factor V Leiden).
Severe Organ Disease	Severe hepatic disease, severe diabetes with vascular damage, severe hypertension.
Malignancy	Known/suspected hormone-sensitive cancers (e.g., breast, genital organs).
Physiological State	Known or suspected Pregnancy; Undiagnosed vaginal bleeding.

Age and Physiological Status Rules

Use is contraindicated during pregnancy and not recommended for lactating/breastfeeding mothers. The medicine is not established for use in adolescents below 18 years and is not indicated for elderly women. Special caution is required for women undergoing major surgery with prolonged immobilization and for those who smoke, particularly if over 35 years old.

Interactions with other medicines and products

Certain medicinal products can affect how Mercilon 28 works or can be affected by Mercilon 28. The most critical interactions are those that may cause a reduction in contraceptive effectiveness or a risk of liver enzyme elevation.

Reduced Contraceptive Effectiveness

Medicines that are known to induce hepatic (liver) enzymes may decrease the blood concentration of the active hormones in Mercilon 28, which can lead to contraceptive failure. These interacting substances include, but are not limited to, the following classes:

• Anticonvulsants: Such as carbamazepine, phenytoin, phenobarbital, and topiramate.
• Anti-Infectives: Including rifampicin and possibly certain others like griseofulvin.
• Herbal Products: Specifically St. John's wort (Hypericum perforatum).

If these drugs must be used, additional non-hormonal barrier methods of contraception should be employed during the period of co-administration and for seven days after stopping the interacting drug. If the seven days extend past the active tablet period, a new pack must be started immediately without a tablet-free break.

Contraindicated Combinations

Mercilon 28 is contraindicated for use with the Hepatitis C virus (HCV) combination drug regimens containing ombitasvir/paritaprevir/ritonavir and dasabuvir, or medicinal products containing glecaprevir/pibrentasvir. The co-administration of these antiviral agents has been associated with a potential for significant elevations of the liver enzyme ALT (alanine aminotransferase).

Other Interactions

Mercilon 28 may affect the measurement of certain laboratory parameters, including levels of sex hormone-binding globulin (SHBG).

Mercilon 28 modulates the hypothalamic-pituitary-ovarian axis through its two active components, the progestogen desogestrel (metabolized to etonogestrel) and the estrogen ethinylestradiol.

Etonogestrel acts as a potent agonist at the intracellular Progesterone Receptor (PR). This interaction suppresses the pulsatile release of Gonadotropin-Releasing Hormone (GnRH) from the hypothalamus. The downstream cascade involves a diminished synthesis and secretion of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) from the anterior pituitary gland, resulting in a systemic reduction of circulating gonadotropins.

Ethinylestradiol serves as an agonist at the Estrogen Receptor (ER) and provides a co-regulator effect. The collective feedback inhibition exerted by both steroids primarily prevents the mid-cycle LH surge, leading to an absence of follicular rupture, a physiological process termed anovulation.

Additional mechanisms involve etonogestrel-mediated alteration of the cervical mucus composition, increasing its viscosity and impeding sperm motility and passage. Furthermore, the combined steroid action induces desynchronized development of the endometrium, reducing its cellular suitability.

How to Use Mercilon 28: Official Administration Guidelines

Mercilon 28 is a combined oral contraceptive administered strictly according to a 28-day cyclic regimen. This regimen consists of taking one tablet daily for 28 consecutive days, following the sequence specified on the blister pack.

Administration Details

Administration Scope	Specification
Route of Administration	Oral
Dosing Schedule	One tablet daily for 28 days (21 active, 7 inactive)
Timing	At approximately the same time each day
Intake Condition	Can be taken with or without food. Tablets must be swallowed whole.

Procedural Steps and Schedule

Each pack contains 21 active tablets (containing 0.15 mg desogestrel and 0.02 mg ethinylestradiol) and 7 inactive tablets. The user must take the tablets in the order directed by the arrows on the strip, ensuring the active tablets are taken first.

• Starting the Pack: Tablet-taking generally begins on Day 1 of the woman's natural cycle. When switching from another contraceptive, specific instructions in the label must be followed.
• Daily Intake: One tablet must be taken every day, regardless of bleeding.
• Continuous Cycle: Once the last (inactive) tablet in a pack is finished, a new Mercilon 28 pack must be started immediately the following day, with no gap between packs.

Missed Active Tablet Protocol

If an active tablet is missed, the course of action is determined by the time elapsed and the tablet's position in the cycle (Week 1, 2, or 3). If less than 12 hours have passed since the usual time, the tablet must be taken immediately, and the course continued normally. If more than 12 hours have passed, specific procedures are mandated, often requiring immediate tablet intake and the use of a backup method for a defined period.

Research Evidence / Overview of Studies for Mercilon 28

Evidence for Use in Contraception (Prevention of Pregnancy)

Research examining the use of the Desogestrel and Ethinyl Estradiol combination was studied for its primary intended use: preventing pregnancy. The research consists of large-scale prospective clinical trials and epidemiological studies that monitored specific measures over defined time intervals. Research populations studied were women of reproductive potential who were seeking contraception.

In these trials, researchers primarily measured the Pregnancy Rate, commonly quantified using the Pearl Index, as the central outcome reflecting daily functioning or activity level. Studies also monitored Ovulation Inhibition by measuring shifts in specific hormonal markers throughout the treatment cycles. These findings describe patterns observed in the studies, reporting the effect on the monthly release of an egg.

The reported outcomes apply only to the populations studied under controlled conditions. Research highlights that changes measured during the study period were based on an assumption of perfect adherence to the daily regimen. Evidence derived from real-world settings indicates that the measured rate of prevention may be lower, as the research does not determine whether an individual will respond similarly when faced with typical challenges like missing a tablet.

Evidence for Use in Menstrual Cycle Regulation

The combination was also evaluated in clinical trials where the measurement of the menstrual pattern was observed in a key outcome. These comparative studies primarily focused on patient-reported outcomes describing perceived discomfort and shifts in bleeding characteristics. The research examined how symptoms evolved in the observed populations, tracking cycle regularity, bleeding duration and intensity, and the frequency of unexpected bleeding or spotting.

Studies report that the research highlights changes measured during the study period, with findings suggesting that a more predictable cycle pattern may become established for many users after the initial months. Research describes that the specific observations often included patterns where patient-reported outcomes described bleeding episodes that were shorter and generally lighter compared to the participant’s cycle characteristics prior to the study.

Long-term Studies and Follow-up Duration

However, data for long-term outcomes regarding cycle pattern measurement and associated symptom monitoring are not fully established beyond the typical one-year follow-up period. While findings describe patterns observed in the studies during the initial phase, information on usage patterns extending over many years remains insufficient in the core regulatory research.

Key Studies & References

1. The comparative efficacy, tolerability, and clinical acceptability of a continuous oral contraceptive containing 20 microg ethinyl estradiol and 150 microg desogestrel
2. Desogestrel And Ethinyl Estradiol: MedlinePlus Drug Information

Official Storage and Disposal Requirements

The storage and disposal instructions for Mercilon 28 are formally documented to ensure the stability and safety of the combined oral contraceptive, as mandated by regulatory authorities.

Storage Constraints

Requirement	Specific Instruction
Temperature	Store at or below 25 C; do not freeze.
Protection	Keep in the original package and store in original pouches to protect from light and moisture.
Safety	The medication must be kept out of the sight and reach of children.
Stability	Do not use Mercilon 28 past its designated expiration date.

Disposal Rules

Unused or expired Mercilon 28 must be disposed of in accordance with local pharmaceutical waste regulations. To prevent environmental harm, the tablets must not be thrown into the household trash or flushed down the toilet or drain. Patients should consult a pharmacist for guidance on proper disposal methods in their area.